AstraZeneca's Lesinurad Gout Treatment Receives EMA Approval
January 22 2015 - 2:46AM
Dow Jones News
By Ian Walker
LONDON--Pharmaceutical company AstraZeneca PLC (AZN.LN) said
Thursday that the European Medicines Agency has approved its
marketing application for Lesinurad, a treatment for gout.
The authorization means AstraZeneca can begin to promote the
medicine within the European Union, as well as in the European
Economic Area countries Iceland, Liechtenstein and Norway.
Write to Ian Walker at ian.walker@wsj.com; @IanWalk40289749
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024